1. Combined pectoralis and serratus anterior plane blocks with or without liposomal bupivacaine for minimally invasive thoracic surgery: A randomized clinical trial.
- Author
-
Marciniak D, Raymond D, Alfirevic A, Yalcin EK, Bakal O, Pu X, Kelava M, Duncan A, Hargrave J, Bauer A, Bustamante S, Lam L, Murthy S, Sessler DI, and Turan A
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Ultrasonography, Interventional, Pain Measurement, Pectoralis Muscles drug effects, Pectoralis Muscles innervation, Thoracic Surgery, Video-Assisted methods, Thoracic Surgery, Video-Assisted adverse effects, Robotic Surgical Procedures methods, Robotic Surgical Procedures adverse effects, Adult, Respiratory Mechanics drug effects, Thoracic Surgical Procedures adverse effects, Thoracic Surgical Procedures methods, Bupivacaine administration & dosage, Anesthetics, Local administration & dosage, Nerve Block methods, Pain, Postoperative prevention & control, Pain, Postoperative etiology, Liposomes administration & dosage, Analgesics, Opioid administration & dosage, Minimally Invasive Surgical Procedures methods, Minimally Invasive Surgical Procedures adverse effects
- Abstract
Background: Minimally invasive thoracic surgery is associated with substantial pain that can impair pulmonary function. Fascial plane blocks may offer a favorable alternative to opioids, but conventional local anesthetics provide a limited duration of analgesia. We therefore tested the primary hypothesis that a mixture of liposomal bupivacaine and plain bupivacaine improves the overall benefit of analgesia score (OBAS) during the first three postoperative days compared to bupivacaine alone. Secondarily, we tested the hypotheses that liposomal bupivacaine improves respiratory mechanics, and decreases opioid consumption., Methods: Adults scheduled for robotically or video-assisted thoracic surgery with combined ultrasound-guided pectoralis II and serratus anterior plane block were randomized to bupivacaine or bupivacaine combined with liposomal bupivacaine. OBAS was measured on postoperative days 1-3 and was analyzed with a linear mixed regression model. Postoperative respiratory mechanics were estimated using a linear mixed model. Total opioid consumption was estimated with a simple linear regression model., Results: We analyzed 189 patients, of whom 95 were randomized to the treatment group and 94 to the control group. There was no significant treatment effect on total OBAS during the initial three postoperative days, with an estimated geometric mean ratio of 0.93 (95% CI: 0.76, 1.14; p = 0.485). There was no observed treatment effect on respiratory mechanics, total opioid consumption, or pain scores. Average pain scores were low in both groups., Conclusions: Liposomal bupivacaine did not improve OBAS during the initial postoperative three days following minimally invasive thoracic procedures. Furthermore, there was no improvement in respiratory mechanics, no reduction in opioid consumption, and no decrease in pain scores. Thus, the data presented here does not support the use of liposomal bupivacaine over standard bupivacaine to enhance analgesia after minimally invasive thoracic surgery., Summary Statement: For minimally invasive thoracic procedures, addition of liposomal bupivacaine to plain bupivacaine for thoracic fascial plane blocks does not improve OBAS, reduce opioid requirements, improve postoperative respiratory mechanics, or decrease pain scores., Competing Interests: Declaration of competing interest Sudish Murthy is a consultant for Advanced Medical Solutions, LLC, an advisor for Lazzaro Medical, and received honoraria from Intuitive Surgical and Medtronic; Alparslan Turan is a consultant for Civco medical and received a research grant from Pacira Pharmaceuticals. Daniel I Sessler - is a consultant for Pacira Pharmaceuticals. Other authors have no conflicts of interest to declare. Sudish Murthy is a consultant for Advanced Medical Solutions, LLC, an advisor for Lazzaro Medical, and received honoraria from Intuitive Surgical and Medtronic; Alparslan Turan is a consultant for Civco medical and received a research grant from Pacira Pharmaceuticals. All other authors declare no conflicts of interest. Pacira Pharmaceuticals was not involved in the data collection, data analysis, preparation of paper, or the decision to submit. The manuscript was not shared with the sponsor., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF